Phase I/II clinical trial to assess the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase (PARP) -inhibitor, in relapsed and refractory chronic lymphocytic leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patients with T-prolymphocytic leukaemia and mantle cell lymphoma.

Trial Profile

Phase I/II clinical trial to assess the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase (PARP) -inhibitor, in relapsed and refractory chronic lymphocytic leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patients with T-prolymphocytic leukaemia and mantle cell lymphoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Olaparib (Primary)
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; T cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms PICCLe
  • Most Recent Events

    • 27 Feb 2016 Status changed from active, no longer recruiting to completed as per ISRCTN: Current Controlled Trials record.
    • 06 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by United Kingdom Clinical Research Network.
    • 06 Nov 2013 Accrual to date is 20% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top